Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

UConn TIP fosters business opportunities

Mostafa Analoui, Executive Director of Venture Development at the University of Connecticut, recently spoke to MetroHartford Alliance about what brought him to Connecticut, his role...

| By Kelley Gipson

JAX and Sanofi team up against cancer

The Jackson Laboratory has signed a research agreement for up to $4.2 million with Sanofi to identify new targets to treat triple-negative breast cancer and...

| By Kelley Gipson

BioCT Legislative Day 3/5/19 in Review

Connecticut’s bioscience industry has seen tremendous progress in recent years, and its key players say they want to work with lawmakers and other stakeholders to...

| By Kelley Gipson

BioCT welcomes Megan Rosengarten to Board

BioCT is pleased to welcome Megan Rosengarten to the BioCT Board of Directors. Megan is a proven leader known for commercializing new insights and opportunities, resulting in...

| By Kelley Gipson

Biohaven receives orphan status for MSA drug

Biohaven Pharmaceutical Holding Company has received orphan drug designation from the FDA for its product candidate verdiperstat (previously BHV-3241), a novel myeloperoxidase inhibitor, for the treatment of...

| By Kelley Gipson

Yale team ‘reengineers’ immune cells

Yale researchers have developed a new way to efficiently engineer immune cells, an advance which enhances the ability to fend off cancer and other diseases....